The Australia Diabetes Care Devices Market size is estimated at USD 704.12 million in 2024, and is expected to reach USD 795.09 million by 2029, growing at a CAGR of 2.46% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the Australia Diabetes Care Devices Market growth. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. Currently as of July 2022, according to the Australian Government Department of Health and Aged Care, a total of 92,35,681 are confirmed cases of COVID-19 since the inception of the pandemic in Australia. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored and maintained regularly, which has underlined the importance of diabetes care devices.
According to Australian National Health Survey 2020-2021, one in twenty (5.3%) people had diabetes. Type 2 diabetes was the most common type of diabetes (85.5%), followed by Type 1 diabetes (11.0%) and type not known by the person reporting (4.1%). The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by physicians. Patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, adjust the doses of insulin, or change the medication, if necessary.
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in developed countries are indications of the increasing usage of diabetic care products. Moreover, the increasing adoption of insulin delivery devices and the rising prevalence of diabetes are driving the market growth. Leading manufacturers are focusing on technological innovations and the development of advanced products to gain a substantial share of the market.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
According to Diabetes Australia, diabetes is the fastest-growing chronic condition in Australia, increasing faster than other chronic diseases such as heart disease and cancer.
Currently, almost 1.9 million Australians contain diabetes, including all types of diagnosed diabetes (almost 1.5 million known and registered) and undiagnosed type 2 diabetes (up to 500,000 estimated). The incidence of diabetes in children and young people is increasing. Almost all children and young people with diabetes include type 1 diabetes. In addition, children are developing type 2 diabetes at younger ages. Children and young people with type 1 and type 2 diabetes contain specific needs, such as access to care from a multidisciplinary pediatric diabetes team and to diabetes treatments and supporting technologies.
One of the main aims of diabetes treatment is to keep blood glucose levels within a specified target range. It can be achieved by balancing food with activity, lifestyle, and diabetes medicines. Blood glucose monitoring readings provide the information required to determine the best management strategy for diabetes. Keeping blood glucose levels within a target range can help reduce a person's risk of developing diabetes-related complications such as diabetic retinopathy, heart diseases, kidney diseases, etc. The number of times people with diabetes use insulin will check their blood glucose levels varies according to several factors. People with type 2 diabetes who do not use insulin may not need to check their blood glucose levels as regularly. However, they may find a period of structured self-monitoring to be helpful.
The Australian Government includes an important role in maintaining access to affordable, high-quality medicines, devices, and services to support people with diabetes in self-management and treatment. It supports people with diabetes through the National Diabetes Services Scheme, the Pharmaceutical Benefits Scheme, the Insulin Pump Program, and Medicare and other funding. State and territory governments also include an important role in preventing and treating diabetes. All levels of Government share responsibility for health services in Australia and ensure that systems work together to produce the best options for people, regardless of their geographic location.
The Australian National Diabetes Strategy is designed in response to diabetes and informs how existing limited healthcare resources can be better coordinated and targeted across all levels of Government. This Strategy identifies the most effective and appropriate interventions to reduce the diabetes impact in the community and leads the way internationally in diabetes prevention, management, and research.
Thus, the market is expected to grow over the forecast period owing to rising prevalence and government support initiatives.
A CGM is used by inserting a small sensor into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems come with a dedicated monitor, and some now display the information via a smartphone app.
Continuous glucose monitoring became a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Various promising glucose-sensing technologies, from traditional electrochemical-based glucose sensors to novel optical and other electrical glucose sensors, are developed, positively impacting the market growth.
The National Diabetes Services Scheme (NDSS) is an initiative of the Australian Government. Once the patient is registered with the NDSS, blood glucose monitoring products can be accessed at subsidized costs. Registration with the NDSS is free and open to everyone in Australia with a Medicare card diagnosed with diabetes. The patient and a healthcare team member must fill out NDSS registration forms. The NDSS subsidizes the blood glucose monitoring strips. People with type 1 diabetes are eligible to access subsidized FGM and CGM.
Furthermore, the current continuous glucose monitoring devices can either display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, which is likely to drive the segment.
This product will be delivered within 2 business days.
The COVID-19 pandemic positively impacted the Australia Diabetes Care Devices Market growth. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. Currently as of July 2022, according to the Australian Government Department of Health and Aged Care, a total of 92,35,681 are confirmed cases of COVID-19 since the inception of the pandemic in Australia. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored and maintained regularly, which has underlined the importance of diabetes care devices.
According to Australian National Health Survey 2020-2021, one in twenty (5.3%) people had diabetes. Type 2 diabetes was the most common type of diabetes (85.5%), followed by Type 1 diabetes (11.0%) and type not known by the person reporting (4.1%). The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by physicians. Patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, adjust the doses of insulin, or change the medication, if necessary.
The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure in developed countries are indications of the increasing usage of diabetic care products. Moreover, the increasing adoption of insulin delivery devices and the rising prevalence of diabetes are driving the market growth. Leading manufacturers are focusing on technological innovations and the development of advanced products to gain a substantial share of the market.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Australia Diabetes Care Devices Market Trends
Increasing Diabetes Prevalence
The Australian Diabetes population is expected to rise by about 2.5% over the forecast period.According to Diabetes Australia, diabetes is the fastest-growing chronic condition in Australia, increasing faster than other chronic diseases such as heart disease and cancer.
Currently, almost 1.9 million Australians contain diabetes, including all types of diagnosed diabetes (almost 1.5 million known and registered) and undiagnosed type 2 diabetes (up to 500,000 estimated). The incidence of diabetes in children and young people is increasing. Almost all children and young people with diabetes include type 1 diabetes. In addition, children are developing type 2 diabetes at younger ages. Children and young people with type 1 and type 2 diabetes contain specific needs, such as access to care from a multidisciplinary pediatric diabetes team and to diabetes treatments and supporting technologies.
One of the main aims of diabetes treatment is to keep blood glucose levels within a specified target range. It can be achieved by balancing food with activity, lifestyle, and diabetes medicines. Blood glucose monitoring readings provide the information required to determine the best management strategy for diabetes. Keeping blood glucose levels within a target range can help reduce a person's risk of developing diabetes-related complications such as diabetic retinopathy, heart diseases, kidney diseases, etc. The number of times people with diabetes use insulin will check their blood glucose levels varies according to several factors. People with type 2 diabetes who do not use insulin may not need to check their blood glucose levels as regularly. However, they may find a period of structured self-monitoring to be helpful.
The Australian Government includes an important role in maintaining access to affordable, high-quality medicines, devices, and services to support people with diabetes in self-management and treatment. It supports people with diabetes through the National Diabetes Services Scheme, the Pharmaceutical Benefits Scheme, the Insulin Pump Program, and Medicare and other funding. State and territory governments also include an important role in preventing and treating diabetes. All levels of Government share responsibility for health services in Australia and ensure that systems work together to produce the best options for people, regardless of their geographic location.
The Australian National Diabetes Strategy is designed in response to diabetes and informs how existing limited healthcare resources can be better coordinated and targeted across all levels of Government. This Strategy identifies the most effective and appropriate interventions to reduce the diabetes impact in the community and leads the way internationally in diabetes prevention, management, and research.
Thus, the market is expected to grow over the forecast period owing to rising prevalence and government support initiatives.
The Continuous Glucose Monitoring Segment is expected to dominate the Australian Diabetes Care Devices Market
The continuous glucose monitoring segment is expected to witness a CAGR of more than 12.7% over the forecast period.A CGM is used by inserting a small sensor into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems come with a dedicated monitor, and some now display the information via a smartphone app.
Continuous glucose monitoring became a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Various promising glucose-sensing technologies, from traditional electrochemical-based glucose sensors to novel optical and other electrical glucose sensors, are developed, positively impacting the market growth.
The National Diabetes Services Scheme (NDSS) is an initiative of the Australian Government. Once the patient is registered with the NDSS, blood glucose monitoring products can be accessed at subsidized costs. Registration with the NDSS is free and open to everyone in Australia with a Medicare card diagnosed with diabetes. The patient and a healthcare team member must fill out NDSS registration forms. The NDSS subsidizes the blood glucose monitoring strips. People with type 1 diabetes are eligible to access subsidized FGM and CGM.
Furthermore, the current continuous glucose monitoring devices can either display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies, like cell phone integration, which is likely to drive the segment.
Australia Diabetes Care Devices Industry Overview
The Australian Diabetes Care Devices Market is moderately fragmented, with few significant and generic players. Manufacturers drive constant innovations to compete in the market. The major players, such as Abbott and Medtronic, underwent many mergers, acquisitions, and partnerships to establish market dominance while adhering to organic growth strategies. It is evident from the R&D spending of these companies.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk A/S
- Sanofi Aventis
- Eli Lilly
- Roche Diabetes Care
- Abbott Diabetes Care
- LifeScan Inc.
- ARKRAY Inc.
- Ascensia Diabetes Care
- AgaMatrix Inc.
- Dexcom Inc.
- Insulet Corporation
- Medtronic
- Ypsomed Holding AG
Methodology
LOADING...
